Literature DB >> 2171422

In vitro response to bactericidal activity of cell wall-active antibiotics does not support the general opinion that enterococci are naturally tolerant to these antibiotics.

R Fontana1, A Grossato, M Ligozzi, E A Tonin.   

Abstract

The incidence of tolerance and paradoxical response to bactericidal activity of penicillin was investigated in 50 clinical isolates of Enterococcus faecalis. Of the isolates tested, 86% exhibited the paradoxical phenomenon whereby there were more survivors at high than at low concentrations above the MIC. Low penicillin concentrations caused decreases equal to or higher than 99.9% in 11 strains, from 99.9 to 99.5% in 23 strains, and lower than 99.5% in 9 strains. Of the total strains, 14% were killed to the same extent by all concentrations above the MIC. The bactericidal activities of other beta-lactams (ampicillin and piperacillin) and other cell wall inhibitors (vancomycin and daptomycin) were also tested against some of these strains. In general, beta-lactams exhibited the best bactericidal activity at 2 x MIC. Piperacillin was the most active, as at 2 x MIC it reduced the original inoculum by 99.9% or more in most of the strains. No concentration of vancomycin above the MIC caused 99.9% killing of the strains, whereas daptomycin was bactericidal at 8 x MIC in most cases. Paradoxical response to bactericidal activity of beta-lactams was abolished by incubation of the inoculum with 2 x MIC before exposure to higher antibiotic concentrations. These findings suggest that enterococci are not always tolerant to cell wall-active antibiotics and that accurate in vitro bactericidal tests may be useful for the choice of appropriate therapy for infections caused by these microorganisms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2171422      PMCID: PMC171865          DOI: 10.1128/AAC.34.8.1518

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Paradoxical response of Enterococcus faecalis to the bactericidal activity of penicillin is associated with reduced activity of one autolysin.

Authors:  R Fontana; M Boaretti; A Grossato; E A Tonin; M M Lleò; G Satta
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

2.  Kinetics of the synergism of penicillin-streptomycin and penicillin-kanamycin for enterococci and its relationship to L-phase variants.

Authors:  W L Hewitt; S J Seligman; R A Deigh
Journal:  J Lab Clin Med       Date:  1966-05

3.  Synergy of penicillin and decreasing concentration of aminoglycosides against enterococci from patients with infective endocarditis.

Authors:  J Y Matsumoto; W R Wilson; A J Wright; J E Geraci; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

4.  Defective killing of enterococci: a common property of antimicrobial agents acting on the cell wall.

Authors:  D J Krogstad; A R Pargwette
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

5.  Paradoxical effect of antibiotics. I. The 'Eagle effect'.

Authors:  P M Shah
Journal:  J Antimicrob Chemother       Date:  1982-10       Impact factor: 5.790

6.  Ampicillin therapy of experimental enterococcal endocarditis.

Authors:  R R Tight
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

7.  Recognition of group D streptococcal species of human origin by biochemical and physiological tests.

Authors:  R R Facklam
Journal:  Appl Microbiol       Date:  1972-06

8.  Antibiotic susceptibility of Streptococcus bovis and other group D streptococci causing endocarditis.

Authors:  C Thornsberry; C N Baker; R R Facklam
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

9.  In vitro activity of modern penicillins and cephalosporins against enterococci.

Authors:  I Haller; S Heinrich
Journal:  Arzneimittelforschung       Date:  1982

10.  Enterococci. Biologic and epidemiologic characteristics and in vitro susceptibility.

Authors:  D Kaye
Journal:  Arch Intern Med       Date:  1982-10-25
View more
  7 in total

1.  Influence of high-level gentamicin resistance and beta-hemolysis on susceptibility of enterococci to the bactericidal activities of ampicillin and vancomycin.

Authors:  E Cercenado; G M Eliopoulos; C B Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

2.  Contribution of the autolysin AtlA to the bactericidal activity of amoxicillin against Enterococcus faecalis JH2-2.

Authors:  Anne-Lise Bravetti; Stéphane Mesnage; Agnès Lefort; Françoise Chau; Catherine Eckert; Louis Garry; Michel Arthur; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

3.  Mechanism of action of BAY v 3522, a new cephalosporin with unusually good activity against enterococci.

Authors:  G Amalfitano; A Grossato; R Fontana
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

4.  Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides.

Authors:  J Gavaldà; C Torres; C Tenorio; P López; M Zaragoza; J A Capdevila; B Almirante; F Ruiz; N Borrell; X Gomis; C Pigrau; F Baquero; A Pahissa
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

5.  Critical importance of in vivo amoxicillin and cefotaxime concentrations for synergy in treatment of experimental Enterococcus faecalis endocarditis.

Authors:  O Join-Lambert; J L Mainardi; C Cuvelier; S Dautrey; R Farinotti; B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

6.  Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis.

Authors:  J L Mainardi; L Gutmann; J F Acar; F W Goldstein
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 7.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.